McClellan: Biosimilar Price Cut Significant; FDA, CMS Could Spur Bigger Cuts

October 20, 2016 at 5:24 PM
Mark McClellan, director of Duke's health policy center and former head of FDA and CMS, said the 15 percent price cut for Pfizer's biosimilar of Johnson & Johnson's Remicade is significant and cautioned the United States might not see as sizable drops in price for biosimilars as for generic drugs. But McClellan, in an interview with Inside Health Policy, also emphasized the country is in the early stages of biosimilar adoption, with uptake and prices likely to be influenced...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.